INT1577

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1975
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 24
Total Number 26
Disease Relevance 7.70
Pain Relevance 3.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (PRL) cytosol (PRL) extracellular region (PRL)
Anatomy Link Frequency
plasma 4
body 4
mammary glands 2
DA neurons 2
pituitary 2
PRL (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 3 98.98 Very High Very High Very High
narcan 11 97.04 Very High Very High Very High
agonist 101 96.88 Very High Very High Very High
Dopamine 280 96.56 Very High Very High Very High
antidepressant 75 95.60 Very High Very High Very High
imagery 22 95.12 Very High Very High Very High
cannabis 66 94.60 High High
gABA 54 94.00 High High
Somatostatin 22 93.52 High High
dopamine receptor 55 87.28 High High
Disease Link Frequency Relevance Heat
Adenoma 37 98.40 Very High Very High Very High
Galactorrhea 582 95.64 Very High Very High Very High
Stress 16 95.00 High High
Reprotox - General 1 129 94.92 High High
Breast Cancer 6 92.96 High High
Cancer 69 91.36 High High
Pituitary Cancer 36 89.88 High High
Congenital Anomalies 26 87.84 High High
Precocious Puberty 1 85.44 High High
Alopecia 1 84.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The dopamine-mediated inhibition of prolactin secretion occurs through the binding of D2 receptors on the membrane of lactotroph cells and involves several signal transduction systems, resulting in inhibition of prolactin gene transcription, reduction of prolactin synthesis and release.
Negative_regulation (reduction) of Gene_expression (synthesis) of prolactin in lactotroph associated with dopamine
1) Confidence 0.59 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0 Pain Relevance 0.30
Elevated levels of endogenous or therapeutic glucocorticoids are associated with clinically relevant immunosuppression [40] through several mechanisms, and at the same time reduce expression and secretion of prolactin [41,42].
Negative_regulation (reduce) of Gene_expression (expression) of prolactin
2) Confidence 0.50 Published 2006 Journal BMC Neurol Section Body Doc Link PMC1501038 Disease Relevance 0.65 Pain Relevance 0.22
In conclusion NLA and enflurane induced a decrease of GH and PRL plasma levels; in both groups the anaesthetic agents, at the dosage used during anaesthesia, blocked the response of these hormones to the surgical stress likely due to a block of the hypothalamic-pituitary response.
Negative_regulation (decrease) of Gene_expression (levels) of PRL in plasma associated with stress
3) Confidence 0.43 Published 1985 Journal Minerva Med. Section Abstract Doc Link 4069417 Disease Relevance 0.26 Pain Relevance 0.07
Similarly, the inability of amphetamine or methylphenidate to decrease serum PRL levels in man suggests important differences between the tuberoinfundibular DA neurons in man and the rat.
Negative_regulation (decrease) of Gene_expression (levels) of PRL in DA neurons
4) Confidence 0.43 Published 1982 Journal Adv. Biochem. Psychopharmacol. Section Abstract Doc Link 6124090 Disease Relevance 0 Pain Relevance 0.34
It was noteworthy that bromocriptine (BRC) therapy started in three patients caused an abrupt decrease in PRL levels.
Negative_regulation (decrease) of Gene_expression (levels) of PRL
5) Confidence 0.43 Published 2006 Journal Turk. J. Pediatr. Section Abstract Doc Link 16848115 Disease Relevance 0.66 Pain Relevance 0.08
The iv administration of 10 microgram/kg clonidine, but not saline, produced a rapid and significant reduction in serum PRL levels.
Negative_regulation (reduction) of Gene_expression (levels) of PRL associated with clonidine
6) Confidence 0.43 Published 1978 Journal Endocrinology Section Abstract Doc Link 217617 Disease Relevance 0 Pain Relevance 0.28
Long-term amisulpride treatment was found to lead to a constant but slow decline in prolactin levels, that remained significantly elevated until the 12th month of treatment and then significantly decreased, but still above normal range, during the first three months after suspension (Schlosser et al 2002).
Negative_regulation (decline) of Gene_expression (levels) of prolactin
7) Confidence 0.43 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.21 Pain Relevance 0.16
A recent study showed that lithium affects variably prolactin secretion, in relation to duration of the therapy: a treatment of less than six months was found to increase prolactin levels as compared to controls, while bipolar patients on long term treatments (<six months) showed a decrease in prolactin levels (Basturk et al 2001).
Negative_regulation (decrease) of Gene_expression (levels) of prolactin
8) Confidence 0.43 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.27 Pain Relevance 0.36
Six months olanzapine was reported effective in reducing prolactin levels from 116 ng/ml to 72 ng/ml also in a woman receiving phenothiazines.
Negative_regulation (reducing) of Gene_expression (levels) of prolactin
9) Confidence 0.43 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376090 Disease Relevance 0.73 Pain Relevance 0
This means that prolactin levels increase or decrease one month before a corresponding change in the number of active lesions is observed on MRI.
Negative_regulation (decrease) of Gene_expression (levels) of prolactin
10) Confidence 0.42 Published 2006 Journal BMC Neurol Section Body Doc Link PMC1501038 Disease Relevance 0.12 Pain Relevance 0.08
Nevertheless, it is possible that the duration of prolactin exposure in the current study was insufficient to increase PTHrP.
Spec (possible) Negative_regulation (duration) of Gene_expression (exposure) of prolactin
11) Confidence 0.40 Published 2007 Journal Int Breastfeed J Section Body Doc Link PMC1950489 Disease Relevance 0.40 Pain Relevance 0
However, prolactin levels in the first subject reached 900.6 ?
Negative_regulation (reached) of Gene_expression (levels) of prolactin
12) Confidence 0.40 Published 2007 Journal Int Breastfeed J Section Body Doc Link PMC1950489 Disease Relevance 0.06 Pain Relevance 0
Combinations of drugs to reduce serum prolactin levels or antagonize the hormones's effect on the breast may be needed to obtain results.
Negative_regulation (reduce) of Gene_expression (levels) of prolactin
13) Confidence 0.38 Published 1975 Journal N. Engl. J. Med. Section Abstract Doc Link 1089886 Disease Relevance 0.84 Pain Relevance 0.07
1 inhibited both IGFBP-1 and PRL production in a time-dependent manner in decidual cells from 1st trimester [26], [36] and term pregnancy [27].
Negative_regulation (inhibited) of Gene_expression (production) of PRL
14) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945765 Disease Relevance 0.14 Pain Relevance 0.10
1 reduces the expression and secretion of PRL, IGFBP-1, and TF by human ESCs decidualized in vitro, as well as primary DSCs obtained from 1st trimester decidua.
Negative_regulation (reduces) of Gene_expression (expression) of PRL in decidua
15) Confidence 0.34 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945765 Disease Relevance 0 Pain Relevance 0
1 (10 ng/ml) down-regulated the expression of transcripts encoding the decidual marker proteins prolactin (PRL), insulin-like growth factor binding protein-1 (IGFBP-1) and tissue factor (TF).
Negative_regulation (down-regulated) of Gene_expression (expression) of PRL
16) Confidence 0.34 Published 2010 Journal PLoS ONE Section Abstract Doc Link PMC2945765 Disease Relevance 0 Pain Relevance 0
These data show that oxytocin is capable of inhibiting the rise in ACTH and cortisol, but not in GH and PRL induced by physical exercise.
Negative_regulation (inhibiting) of Gene_expression (rise) of PRL
17) Confidence 0.33 Published 1988 Journal Acta Endocrinol. Section Abstract Doc Link 2847472 Disease Relevance 0 Pain Relevance 0.40
1-dependent decrease in expression of PRL mRNA (Figure 4C) and the amount of PRL released (Figure 4D) remained at control levels; the amount of PRL released by cells transfected with an siRNA directed against MAPK was similar to that released by cells incubated with TGF?
Negative_regulation (decrease) of Gene_expression (expression) of PRL mRNA
18) Confidence 0.33 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2945765 Disease Relevance 0 Pain Relevance 0
Cross-ApEn synchrony between TSH and GH did not differ between patients and controls, but TSH and PRL synchrony was reduced in patients.
Negative_regulation (reduced) of Gene_expression (synchrony) of PRL
19) Confidence 0.31 Published 2008 Journal Pituitary Section Abstract Doc Link PMC2712623 Disease Relevance 0.37 Pain Relevance 0
Mean plasma prolactin levels were also observed to decrease over the course of the open-label phases.
Negative_regulation (decrease) of Gene_expression (levels) of prolactin in plasma
20) Confidence 0.28 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2656329 Disease Relevance 0.45 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox